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Abstract. Background: Metastasis-associated protein 1
(MTA1) plays an important role in tumourigenesis and
progression of certain cancer types. In the current study, we
analyzed the relationship between MTA1 expression and
disease progression of colorectal cancer (CRC). Materials
and Methods: CRC tissues (n=93) and adjacent normal
colorectal tissues (n=70) were analyzed by quantitative real-
time polymerase chain reaction. MTA1 knockdown was
established in RKO and HT115 cells using MTA1 siRNA.
Results: The expression of MTA1 was significantly increased
in CRC tissues compared to paired normal colorectal
tissues, but decreased expression of MTA1 was correlated
with poor prognosis (higher lymph node involvement stage,
TNM stage, local invasion and recurrence) that was
associated with increased expression of VEGFC and -D and
the receptor VEGFR3. Conclusion: MTA1 is up-regulated in
CRC. MTA1 expression is inversely associated with
lymphatic metastases and the expression of VEGFC,
VEGFD and VEGFR3. 
Worldwide, colorectal cancer (CRC) is the third most
commonly diagnosed cancer in males and the second in
females, with over 1.3 million new cancer cases and 693,900
deaths estimated to have occurred in 2012 (1). The highest
incidence rates are found in Australia and New Zealand,
Europe, and North America, whereas the lowest rates are
found in Africa and South-Central Asia (1). Rates are
substantially higher in males than in females (1). Colorectal
cancer is the second most common cause of cancer-related
death in the UK. Around 16,200 people died of CRC in 2012
in the UK (2). In China, information from the National
Central Cancer Registry indicates that colorectal cancer is
the fifth most common cause of cancer-related death in men
and the fourth in women (3).
The metastasis-associated protein (MTA) family consists
of three well-known members, MTA1, MTA2, and MTA3.
MTA1 gene was first identified by differential cDNA library
screening using the rat mammary adenocarcinoma metastatic
system and was found to be positively associated with breast
cancer invasion and metastasis (4). MTA1 is an essential part
of the nucleosome remodelling and histone deacetylation
complex and is considered to act as a negative transcriptional
regulator (5). In the past two decades, MTA1 overexpression
has been demonstrated in a variety of human malignancies
and may be associated with vascular endothelial growth
factor (VEGF) (6). Both nuclear expression of MTA1 protein
and increased frequency of tumour microvessels were seen
in higher-grade human ductal breast carcinoma sections
using immunohistochemistry (IHC) analysis (7). Furthermore
an in vitro study has shown that MTA1 up-regulates
expression of VEGF and its receptor FLT1 via extracellular
signal-regulated kinase (ERK) and c-Jun N-terminal kinase
(JNK) pathway in HEK-293 and MCF-7 cells (7). The
protein level of MTA1 and VEGFA was consistently lower
in invasive ductal carcinomas with high maspin expression
compared to tumours that had lost maspin expression (7).
Furthermore, decreased MTA1 protein expression
accompanied by reduced angiogenesis has been observed in
prostate cancer tumours in castrated and interleukin 17
(IL17) receptor C-deficient mice, suggesting that MTA1
might be a target gene of the IL17 signaling pathway (8).
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VEGFC was initially purified and cloned from human
prostatic carcinoma cells in 1996 (9). VEGFC and its receptor
VEGFR3 play an important role in angiogenesis and
lymphangiogenesis (9). The VEGFC–VEGFR3 axis enhances
tumour growth and metastases in certain types of solid
cancers (10). 
Aberrant expression of MTA1 has also been observed in
CRC. MTA1 mRNA was highly expressed in 14 out of 36
(38.9%) CRCs and was associated with deeper invasion
through the intestine wall and a higher rate of lymph node
metastasis (11). Higher MTA1 mRNA levels were seen in
CRC tumours compared to normal colorectal mucosa in a
cohort of 40 CRC samples (12). Positive IHC staining of
MTA1 was shown in 38 out of 74 (51.4%) CRCs. MTA1
expression was correlated with the depth of tumor invasion
and vascular invasion (13). Furthermore, the 5-year survival
rate in the MTA1-positive group (50.5%) was significantly
lower compared to the MTA1-negative group (73.1%) (13).
MTA1 expression analysis by IHC indicated that MTA1
expression was significantly higher in moderately and poorly
differentiated tumours and live-metastatic tumours compared
to normal colonic tissues in a cohort which comprised of 18
normal colon tissues and 91 tumor samples (14). MTA1
overexpression in HCT-116 cells enhanced proliferation,
adhesion, migration and invasion, while silencing of MTA1
inversely affected these cellular functions (14). In an
examination of 81 CRC samples using IHC, MTA1 and
VEGFC expression levels were correlated with lymph node
metastasis and Dukes' stages (15). Furthermore, knockdown
of MTA1 in HCT116 cells resulted in decreased VEGFC
expression, whilst the opposite effect was seen in LoVo
MTA1-overexpressing cells (15).
In the current study, we aimed to determine the expression
of MTA1 and VEGFC in CRC. MTA1 and VEGFC expression
in in a clinical cohort of 93 CRC tissues and 70 normal
colorectal tissues was determined using quantitative real-time
polymerase chain reaction (QPCR) and the association with
the clinical and pathological features was further analysed.
MTA1 knockdown was established in RKO cells using anti-
MTA1 small interfering RNA (siRNA) and VEGFC transcript
level was also determined. The effect of MTA1 knockdown on
cell growth, migration and invasion were also assessed.
Materials and Methods
Cell lines and culture conditions. Human colon cancer cell lines
RKO, Caco-2, HRT-18 and HT115 were purchased from the
European Collection of Cell Cultures (Salisbury, UK) and were
cultured at 37˚C, with 5% CO2 and 95% humidity. The wild-type
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% foetal calf serum (PAA
Laboratories Ltd., Somerset, UK), amphotericin B, penicillin and
streptomycin. 
Fresh human colorectal cancer tissues. Colorectal cancer tissues
(n=93) and normal background tissues (n=70) were collected
immediately after surgery and stored at −80˚C until use. All
specimens were verified using haematoxylin and eosin (H&E)-
stained frozen sections by consultant pathologists. Histological
information was obtained from pathology reports. The study was
approved by the South East Wales Local Research Ethics
Committee (05/WSE03/92) and consent was obtained from the
patients. 
RNA isolation, reverse transcription-polymerase chain reaction (RT-
PCR) and QPCR. RNA was extracted from confluent cells in a 
25 cm2 flask using total RNA isolation (TRI) reagent and following
the protocol provided (Sigma-Aldrich, Dorset, UK). Fresh frozen
tissues were first homogenised in the TRI reagent by a handheld
homogenizer. cDNA was synthesised from 1 μg RNA by using a
first-strand DNA systhesis kit (BioRad, Hemel Hempstead, UK).
Quantitative analysis of MTA1 mRNA expression in CRC tissues
was determined by QPCR using Amplifor™-based technologies, in
which a 6-carboxy-fluorescine-tagged Uniprimer™ (Biosearch
Technologies, Inc., Petaluma, CA, USA) was used as a probe
together with a pair of target-specific primers and reverse primer
with an additional Z-sequence (actgaacctgaccgtaca). The quality of
cDNA samples was verified using glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as a housekeeping gene. All the primers
are listed in Table I.
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Table I. Primers used for polymerase chain reaction (PCR) and quantitative real time PCR (QPCR).
Gene Forward primer Reverse primer
MTA1 (QPCR) GAGGAACAGCTCCCGATG ACTGAACCTCACCGTACAGAAGGGGAAATAGAAGAGGA
VEGFC (PCR) TTTGCCAATCACACTTCCTG CAGGCACATTTTCCAGGATT
VEGFC (QPCR) GGAAAGAAGTTCCACCACCA ACTGAACCTGACCGTACAGAAAATCCTGGCTCACAAGC
VEGFD (PCR) TGGAACGATCTGAACAGCAG TTCTTCAGGGATCTGGATGG
VEGFR2 (QPCR) CTTGCTCAAGACAGGAAGAC ACTGAACCTGACCGTACACCCAATACTTGTCGTCTGAT
VEGFR3 (QPCR) AGCATCGTGTGGTACAAAG ACTGAACCTGACCGTACACTCAGCTTCTGGTTGGAGT
GAPDH (PCR) GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT
β-Actin (QPCR) CATTAAGGAGAAGCTGTGCT ACTGAACCTGACCGTACAGCTCGTAGCTCTTCTCCAG
MTA1: Metastasis-associated protein 1; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; GAPDH: glyceraldehyde 3-phosphate
dehydrogenase.
MTA1 knockdown using siRNA. MTA1 siRNA and control siRNA
were bought from Santa Cruz Biotechnology, Inc. (Heidelberg,
Germany). Transfection of MTA1 siRNA was conducted following the
manufacturer's protocol. Briefly, 7×105 cells were seeded to each well
of a 6-well plate in antibiotic-free DMEM supplemented with 10%
foetal calf serum and incubated overnight. Lyophilized MTA1 siRNA
was dissolved in 330 μl of the RNAse-free water, and 6 μl of MTA1
siRNA was added to 94 μl siRNA transfection medium to make
solution A. Meanwhile, 3 μl of siRNA transfection reagent was added
to 97 μl siRNA transfection medium to make solution B. Solution A
and solution B were mixed and incubated for 30 min at room
temperature and this was subsequently used to transfect cells. After
incubation for 72 h, cells were harvested for expression analysis. 
Western blot analysis. The protein concentrations in the cell lysates
were determined using the DC protein assay kit (Bio-Rad) and an
ELx800 spectrophotometer (Biosearch Technologies, Inc.). After
separation using sodium dodecyl sulfate polyacrylamide gel
electrophoresis, proteins were blotted and probed with the antibody to
MTA1 (1:500; Santa Cruz Biotechnology, Inc.), antibody to VEGFC
(1:500; Santa Cruz Biotechnology, Inc.), and antibody to GAPDH
(1:1,000; Santa Cruz Biotechnology, Inc.) as a housekeeping gene
control, followed by a peroxidase-conjugated secondary antibody
(1:2,000; Sigma-Aldrich Ltd., Dorset, UK). Protein bands were
visualised using a chemiluminescence detection kit (Luminata,
Millipore Ltd., Feltham, UK) and photographed using Syngene imager
(Syngene International Ltd., Cambridge, UK).
In vitro cell growth assay. CRC cells were seeded into a 96-well plate
at a density of 3,000 cells/200 μl per well. Cells were incubated for 1,
3 and 4 days, and were then fixed with 4% formaldehyde. Following
staining with 0.5% crystal violet, absorbance was determined at a
wavelength of 540 nm using an ELx800 spectrophotometer.
In vitro invasion assay. The procedure for the in vitro invasion assay
has previously been described (16). Culture inserts with 8-μm pores
were pre-coated with 50 μg of Matrigel Matrix Basement Membrane
(BD Bioscience, Oxford, UK) and air-dried. Following a rehydration,
3×105 cells were seeded into each insert. After incubation for 72
hours, cells that had migrated through the matrix to the other side of
the insert were fixed, stained and counted.
Wound-healing assay. The assay was performed as previously
described (16). A total of 3×105 cells were seeded into 96-well
plates and incubated overnight. The monolayer of cells was scraped
with a 10 μl pipette tip to ensure a linear wound. The migration of
cells was photographed using a time-lapse video recorder and
analysed using Optimas 6.0 motion analysis (Meyer Instruments,
Inc., Houston, TX, USA).
Statistical analysis. Student t-test and one-way ANOVA analysis
were performed using SPSS statistical software (SPSS version 22.0;
IBM Inc., Armonk, NY, USA). Data are shown as mean±SE.
Differences were considered to be statistically significant at p<0.05.
Results
The correlation of mRNA of MTA1 and clinical parameters in
CRC. The transcript level of MTA1 in a cohort of 93 CRC
tissues and 70 adjacent normal colorectal tissues was
determined using QPCR which was normalised against
corresponding β-actin. The association of expression with the
clinical and pathological features was analyzed using one-way
ANOVA (Table II). The median follow-up period was 21.7
months (range=0.7-88 months) for the current cohort. Higher
levels of MTA1 transcript were observed in the CRC samples
compared to normal colorectal tissue (p=0.013). However, the
level of MTA1 transcripts were decreased in tumours with
lymph node involvement (N1 and N2) in comparison no-lymph
node involvement (N0) (p=0.021 and 0.016, respectively). In
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Table II. Correlation of mRNA expression of metastasis-associated
protein 1 (MTA1) (copies) and clinical parameters.
Category No. MTA1, mean±SE p-Value
T/N
Normal 70 7.1±3.31
Tumour 91 2983±1178 0.013*
Location
Left colon 22 1823±1511
Right colon 28 5325±2526 0.24
Transverse colon 2 962±9626 0.64
Rectum 21 3611±3501 0.64
Dukes' stage
A 7 13658±7539 
B 32 5174±27691 0.33
C 32 164±113 0.12
Tumour stage
T1 2 12457±12036
T2 10 14183±6545 0.92
T3 40 2407±1872 0.56
Τ4 17 192±121 0.49
Lymph node involvement stage
N0 38 6873±2715
N1 16 290±224 0.021*
N2 15 31.9±19.7 0.016*
N12 31 165±116 0.018*
TNM stage
I 9 18526±6850
II 29 3256±25746 0.063
III 26 179±139 0.028*
IV 6 96.0±42.26 0.027*
Clinical outcome
No invasion 49 5334±2139
Invasion 26 216±141 0.021*
Disease-free 34 2891±1700
Incidence 23 3979±3188 0.77
No recurrence 57 4555±1854
Local recurrence 7 282±274 0.026*
No metastasis 49 3683±1602
Metastasis 19 4299±3863 0.88
Alive 35 1487±1034
Death 22 4162±3331 0.45
Non therapy 42 4309±1855
Neoadjuvant chemoradiotherapy 13 427±424 0.047*
*Significant at p<0.05.
line with this finding, decreased levels of MTA1 transcript were
also seen in more advanced tumours (T3 and T4) according to
the TNM staging in comparison with that of tumours at an
early stage (T1) (p=0.028 and 0.027, respectively). Similarly,
decreased MTA1 expression was also seen in tumours of Dukes'
stage B and C compared to Dukes' stage A tumours. Reduced
levels of MTA1 transcript were seen in locally invasive tumours
compared non-invasive tumours (p=0.021). In terms of clinical
outcomes, patients with tumours with local recurrence
exhibited lower MTA1 expression compared to those that
remained disease-free (p=0.026). Lower MTA1 expression was
seen in the group of patients who received neoadjuvant
chemoradiotherapy compared to the non-treated group
(p=0.047). No correlation with survival of patients was
observed for MTA1 expression in the current cohort.
The correlation between MTA1 and VEGF, VEGFR in CRC.
The transcript levels of VEGF family members and their
receptors (VEGFA-D and VEGFR1-3) in the CRC cohort
were also determined using QPCR. Their correlation with
MTA1 expression was analyzed using Spearman correlation
analysis (Table III). A significant correlation was found
between increased expression of MTA1 and reduced
expression of VEGFC. Similarly, the expression of MTA1
was also significantly inversely correlated with that of
VEGFD and VEGFR3. Conversely, the expression of MTA1
was significantly positive correlated with that of VEGFR2.
No correlation was found between the MTA1 expression and
other VEGF and VEGFRs.
MTA1, VEGF and VEGFR expression in CRC cell lines. The
expression of MTA1, VEGFs and VEGFRs by CRC cell lines
was also examined using PCR. Similar transcript levels of
MTA1 were observed in RKO, Caco-2, HRT-18 and HT115
cell lines (Figure 1A). VEGFC expression was higher in
RKO cells compared to Caco-2, HRT-18 and HT115 cells.
Expression of VEGFD, VEGFR2 and VEGFR3 was found to
be very low or absent from these CRC cell lines.
MTA1 knockdown in RKO and HT115 cells. Reduced MTA1
expression was seen in the RKO and HT115 cells transfected
with MTA1 siRNA. The altered MTA1 expression was
verified using RT-PCR (Figure 1B and 1E). Reduced MTA1
transcripts in RKO MTA1 knockdown cells were also
confirmed using real-time PCR (Figure 1C). Due to lower
expression or absence of VEGFs and VEGFRs in other cell
lines, only expression of VEGFC was determined in RKO
cells. Following knockdown of MTA1, an increased
expression of VEGFC mRNA was evident both in the PCR
(Figure 1B) and also real-time PCR analyses (Figure 1C).
However, subsequent determination of protein levels in these
cells did not exhibit any difference in VEGFC expression at
the protein level. In line with the PCR and real-time PCR
results, reduced protein expression of MTA1 was seen in the
RKO MTA1 knockdown cells.
The effect of MTA1 knockdown on growth, migration and
invasion of RKO cells. Cellular functions, including in vitro
growth, migration and invasion, were determined using in
vitro functional assays. Knockdown of MTA1 in RKO cells
resulted in a decreased growth compared with control cells
(Figure 2). In subsequent analyses of cell migration, reduced
migration was seen in the RKO MTA1 knockdown cells
compared with the control cells over a period up to 16 h
(Figure 3). Similarly to the observation in the functional tests
of migration, a decrease was also seen in the invasion of
RKO MTA1 knockdown cells in comparison to control cells
(p<0.001; Figure 4).
Discussion
Several genes, including activation of KRAS and inactivation
of adenomatous polyposis coli (APC) and p53, play profound
roles in tumourigenesis and progression in CRC (17, 18).
The expression of many genes in CRC is changed compared
to normal tissues, as assessed using cDNA microarrays (19,
20). This suggests that aberrations in the expression of
multiple genes or their protein functions are required during
tumourigenesis and progression of CRC. MTA1 is one of the
genes that has been found to be overexpressed in CRC
tissues and cell lines. Overexpression of MTA1 is positively
correlated with cell invasion, higher metastasis rate, poorer
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Table III. Correlation of metastasis-associated protein 1 (MTA1) expression with expression of vascular endothelial growth factor (VEGF), and its
receptor.
VEGFA VEGFB VEGFC VEGFD VEGFR1 VEGFR2 VEGFR3
Correlation coefficient with MTA1 0.0911 −0.173 −0.208 −0.321 0.00518 0.413 –0.266
p-Value 0.473 0.114 0.0451* 0.00886* 0.961 0.000107* 0.0312*
Number of samples 64 84 93 66 93 84 66
All the values are normalized to those for glyceraldehyde 3-phosphate dehydrogenase. *Significant at p<0.05.
prognosis, and VEGFC expression (11-15). The present
study shows that the expression of MTA1 is significantly
elevated in CRC tissues compared to paired normal
colorectal tissues. This is in line with findings by other
researchers, suggesting that MTA1 plays a role in
tumourigenesis and development of CRC (12, 13). However,
further analysis of MTA1 expression, comparing its
expression in tumours at different stages of disease, showed
a reduced expression of MTA1 transcripts in locally advanced
tumours with invasion, raising the question of whether MTA1
plays the same role during the whole process of CRC
development and progression. A different role may be played
by MTA1 during early stages of disease progression, for
example, when CRC cells are dissociating from the primary
tumour and begin to invade through surrounding tissue. This
is also reflected in the analyses of MTA1 expression levels
Li et al: MTA1 and Lymphatic Metastasis of CRC
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Figure 1. Expression of metastasis-associated protein 1 (MTA1), vascular
endothelial growth factors (VEGFs) and VEGF receptors (VEGFRs) in
CRC cells. A: MTA1, VEGFC, VEGFD, VEGFR2 and VEGFR3
expression in RKO, Caco-2, HRT-18 and HT115 cell lines were
determined using reverse transcription-polymerase chain reaction (RT-
PCR). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as a housekeeping gene. B: The expression of MTA1, VEGFC, VEGFD,
VEGFR2 and VEGFR3 in RKO cells transfected with MTA1 siRNA (kd)
and control siRNA was determined using RT-PCR. C: The expression of
MTA1 and VEGFC in RKO cells was also quantified using real-time
quantitative PCR. D: Knockdown of MTA1 and consequent effects on the
expression of VEGFC at their protein levels were also examined using
western blot analysis. E: MTA1, VEGFC, VEGFD, VEGFR2 and
VEGFR3 expression in HT115 cells was also assessed using RT-PCR.
Significantly different at: *p<0.05, and ***p<0.001. WT: Wild-type cells.
Figure 3. Effect of metastasis-associated protein 1 (MTA1) knockdown on
cell migration. A: The wound-healing assay at 0, 8 and 16 h in RKO
control and RKO MTA1 knockdown (kd) cells (×100). B: Quantification of
wound closure. Each cell line was tested in triplicate for an individual
experiment. Three experiments were performed. Representative images (A)
and average migration (mean and standard error of mean, B) are shown.
Significantly different at: **p<0.01, and ***p<0.001.
Figure 2. Influence of metastasis-associated protein 1 (MTA1)
knockdown on in vitro cell growth. The cell growth at day 3 and day 4
in RKO control and RKO MTA1 knockdown (kd) cells. Three
experiments were performed. The mean and standard error of mean
(error bars) are shown. Significantly different at: *p<0.05, and
**p<0.01.
in tumours according to TNM staging, and also in patients
who received neoadjuvant chemoradiotherapy.
We further investigated the influence of MTA1 on
functions of CRC cells by interfering with its expression
using siRNA. Knockdown of MTA1 in RKO cells resulted in
a reduction of in vitro growth, migration and invasion. This
appears to provide supportive evidence for its positive role
in CRC cell function that has been evident in other studies
(12, 13) and also in the current study, by comparing its
expression in tumours with normal colonic tissues.
Moreover, an even more complicated mechanism may
underlie these observations. For instance, MTA1 may play a
different role when cancer cells interact with surrounding
tissues and cells of other types within or surrounding the
tumours. Our current study suggests a potential role for this
molecule in the lymphatic metastasis of CRC. 
Lymph node metastases are commonly seen in CRC and
have been utilised as a prognostic factor and also a criterion
for the selection of adjuvant therapies (21). In the current
study, reduced expression of MTA1 was observed in tumours
with lymph node metastases. Decreased expression was also
seen in more advanced tumours in comparison to tumours at
an early stage according to their TNM staging. We then
analysed the link between MTA1 expression and VEGFs and
VEGFRs in the current cohort of CRC. In line with its
reduced expression in tumours with lymphatic metastases, an
inverse correlation was seen between MTA1 expression and
that of VEGFC, VEGFD and VEGFR3. This suggests that
reduced MTA1 expression in the tumours facilitates
lymphangiogenesis and dissemination of CRC cells via
lymphatic vessels. MTA1 may play a negative role in tumour-
associated lymphangiogenesis and consequent lymphatic
metastasis.  
VEGFC can regulate both angiogenesis and lymphangio-
genesis through VEGFR3-mediated signaling (9, 10). Du et
al. reported that MTA1 regulates lymphangiogenesis by
inducing VEGFC expression in CRC (15). However, a
negative correlation between MTA1 and VEGFC was
revealed in the current cohort of CRC by quantitative
analysis of their transcripts. Further investigation of VEG-C
in the RKO CRC cell line, which expresses both MTA1 and
VEGFC, confirmed such a correlation existing in this CRC
cell line. This suggests that at least in some CRC cells,
MTA1 can negatively regulate expression of VEGFC. On the
other hand, we also observed a positive correlation between
MTA1 and VEGFR2 in the current CRC cohort. Dual roles
may, therefore, be played by MTA1 in coordinating
angiogenesis and lymphangiogenesis.
In conclusion, MTA1 expression is elevated in CRC.
Reduced MTA1 expression in CRC is associated with local
invasion and lymphatic metastasis. It has been suggested that
differential roles may be played by MTA1 at different stages
of the disease, i.e. tumourigenesis and progression,
lymphangiogenesis and angiogenesis. The exact mechanisms
underlying such controversial roles require further
investigation employing different techniques (i.e. robust
epigenomics and proteomics analysis), co-culture, 3-D
models and also in vivo experiments.
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